Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma

Trial Profile

Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2016 Status changed from recruiting to completed.
    • 10 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 10 Feb 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top